|
|
Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers. Journal of human hypertension. 2012. Liu T, et al. [Article:22217675@PubMed] |
|
|
PharmGKB summary: caffeine pathway. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. [Article:22293536@PubMed] |
|
|
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenetics and genomics. 2012. McDonagh Ellen M, et al. [Article:22547082@PubMed] |
|
|
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012. Zhang Wei, et al. [Article:22248286@PubMed] |
|
|
Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals. Therapeutic drug monitoring. 2012. Heil Sandra G, et al. [Article:22354160@PubMed] |
|
|
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. British journal of cancer. 2011. Kim K-p, et al. [Article:21326246@PubMed] |
|
|
Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age. Clinical pharmacology and therapeutics. 2011. Desta Z, et al. [Article:21975350@PubMed] |
|
|
Genistein alters caffeine exposure in healthy female volunteers. European journal of clinical pharmacology. 2011. Chen Yao, et al. [Article:21222115@PubMed] |
|
|
Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. European journal of clinical pharmacology. 2011. Tanii Hiromi, et al. [Article:21494765@PubMed] |
|
|
Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. European journal of endocrinology / European Federation of Endocrine Societies. 2011. Liu Tao, et al. [Article:21964962@PubMed] |
|
|
Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. Journal of the National Cancer Institute. 2011. Wassenaar Catherine A, et al. [Article:21747048@PubMed] |
|
|
PharmGKB summary: carbamazepine pathway. Pharmacogenetics and genomics. 2011. Thorn Caroline F, et al. [Article:21738081@PubMed] |
|
|
The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenetics and genomics. 2011. Bloom Joseph, et al. [Article:21597399@PubMed] |
|
|
Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. Pharmacogenomics. 2011. Wang Huijuan, et al. [Article:21521021@PubMed] |
|
|
Pharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacological reports : PR. 2011. Baer-Dubowska Wanda, et al. [Article:21602587@PubMed] |
|
|
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. [Article:21388883@PubMed] |
|
|
Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction (Abingdon, England). 2010. Liu Tao, et al. [Article:21205058@PubMed] |
|
|
Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. British journal of clinical pharmacology. 2010. Hukkanen Janne, et al. [Article:20233178@PubMed] |
|
|
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?. Cancer chemotherapy and pharmacology. 2010. Ishii Yukimoto, et al. [Article:19921195@PubMed] |
|
|
The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clinical neurology and neurosurgery. 2010. Tan Lan, et al. [Article:20089352@PubMed] |
|
|
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. [Article:20981002@PubMed] |
|
|
Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clinical pharmacology and therapeutics. 2010. Lerman C, et al. [Article:20336063@PubMed] |
|
|
Efavirenz in the therapy of HIV infection. Expert opinion on drug metabolism & toxicology. 2010. Rakhmanina Natella Y, et al. [Article:20001610@PubMed] |
|
|
PharmGKB summary: fluoropyrimidine pathways. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:20601926@PubMed] |
|
|
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010. Elens Laure, et al. [Article:20860463@PubMed] |
|
|
New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics. 2010. Mwenifumbo Jill C, et al. [Article:20136358@PubMed] |
|
|
Nicotine addiction. The New England journal of medicine. 2010. Benowitz Neal L. [Article:20554984@PubMed] |
|
|
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS (London, England). 2009. Kwara Awewura, et al. [Article:19779319@PubMed] |
|
|
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. British journal of clinical pharmacology. 2009. Kwara Awewura, et al. [Article:19371316@PubMed] |
|
|
Coffee intake, variants in genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. Cancer causes & control : CCC. 2009. Kotsopoulos Joanne, et al. [Article:18941913@PubMed] |
|
|
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer chemotherapy and pharmacology. 2009. Jeong Seongwook, et al. [Article:19198839@PubMed] |
|
|
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical pharmacology and therapeutics. 2009. Ho M K, et al. [Article:19279561@PubMed] |
|
|
Pharmacoepigenetics: its role in interindividual differences in drug response. Clinical pharmacology and therapeutics. 2009. Gomez A, et al. [Article:19242404@PubMed] |
|
|
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clinical pharmacology and therapeutics. 2009. Arab-Alameddine M, et al. [Article:19225447@PubMed] |
|
|
Polymorphic drug metabolism in anaesthesia. Current drug metabolism. 2009. Restrepo Juan G, et al. [Article:19442086@PubMed] |
|
|
Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Current drug metabolism. 2009. Di Yuan Ming, et al. [Article:19702528@PubMed] |
|
|
Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenetics and genomics. 2009. Swan Gary E, et al. [Article:19300303@PubMed] |
|
|
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and genomics. 2009. di Iulio Julia, et al. [Article:19238117@PubMed] |
|
|
Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics. 2009. Mehlotra Rajeev K, et al. [Article:19290792@PubMed] |
|
|
Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics. 2009. Kong Sun-Young, et al. [Article:19604090@PubMed] |
|
|
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. The Journal of infectious diseases. 2009. Leger Paul, et al. [Article:19659438@PubMed] |
|
|
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. The pharmacogenomics journal. 2009. Al Koudsi Nael, et al. [Article:19365400@PubMed] |
|
|
Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems. 2009. Murai K, et al. [Article:19845430@PubMed] |
|
|
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. [Article:18695978@PubMed] |
|
|
CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer science. 2008. Fujita Ken-ichi, et al. [Article:18380793@PubMed] |
|
|
Clinical pharmacology of artemisinin-based combination therapies. Clinical pharmacokinetics. 2008. German Polina I, et al. [Article:18193915@PubMed] |
|
|
Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clinical pharmacology and therapeutics. 2008. Benowitz N L. [Article:18305452@PubMed] |
|
|
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clinical pharmacology and therapeutics. 2008. Mwenifumbo J C, et al. [Article:17522595@PubMed] |
|
|
The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clinical pharmacology and therapeutics. 2008. Kaida Y, et al. [Article:18212800@PubMed] |
|
|
Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clinical pharmacology and therapeutics. 2008. Patterson F, et al. [Article:18388868@PubMed] |
|
|
Pyrethroids: cytotoxicity and induction of CYP isoforms in human hepatocytes. Drug metabolism and drug interactions. 2008. Das Parikshit C, et al. [Article:19326768@PubMed] |
|
|
Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Human mutation. 2008. Mwenifumbo Jill C, et al. [Article:18360915@PubMed] |
|
|
Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter. Molecular pharmacology. 2008. Onica Tania, et al. [Article:17978169@PubMed] |
|
|
A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenetics and genomics. 2008. Ho Man Ki, et al. [Article:18216723@PubMed] |
|
|
Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine. Pharmacogenetics and genomics. 2008. Endo Takuro, et al. [Article:18698229@PubMed] |
|
|
In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomedical chromatography : BMC. 2007. Begas E, et al. [Article:17221922@PubMed] |
|
|
Effects of eleven isothiocyanates on P450 2A6- and 2A13-catalyzed coumarin 7-hydroxylation. Chemical research in toxicology. 2007. von Weymarn Linda B, et al. [Article:17672516@PubMed] |
|
|
Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2007. Brown Pamela J, et al. [Article:17717079@PubMed] |
|
|
Human CYP2A6 is induced by estrogen via estrogen receptor. Drug metabolism and disposition: the biological fate of chemicals. 2007. Higashi Eriko, et al. [Article:17646279@PubMed] |
|
|
Involvement of CYP2A6 in the formation of a novel metabolite, 3-hydroxypilocarpine, from pilocarpine in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2007. Endo Takuro, et al. [Article:17178767@PubMed] |
|
|
Population pharmacokinetics of nicotine and its metabolites I. Model development. Journal of pharmacokinetics and pharmacodynamics. 2007. Levi Micha, et al. [Article:17206524@PubMed] |
|
|
Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells. Molecular nutrition & food research. 2007. Moon Young Jin, et al. [Article:17340576@PubMed] |
|
|
Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenetics and genomics. 2007. Ring Huijun Z, et al. [Article:18004205@PubMed] |
|
|
CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?. Pharmacogenomics. 2007. Farinola Nicholas, et al. [Article:17286538@PubMed] |
|
|
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & therapeutics. 2007. Ingelman-Sundberg Magnus, et al. [Article:18001838@PubMed] |
|
|
Structure of the human lung cytochrome P450 2A13. The Journal of biological chemistry. 2007. Smith Brian D, et al. [Article:17428784@PubMed] |
|
|
CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. The Journal of pharmacology and experimental therapeutics. 2007. Zhang Xiuling, et al. [Article:17671098@PubMed] |
|
|
3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochemical and biophysical research communications. 2006. Wang Jue, et al. [Article:16378601@PubMed] |
|
|
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clinical pharmacology and therapeutics. 2006. Benowitz Neal L, et al. [Article:17112802@PubMed] |
|
|
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clinical pharmacology and therapeutics. 2006. Nakajima Miki, et al. [Article:16952495@PubMed] |
|
|
Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clinical pharmacology and therapeutics. 2006. Johnstone Elaine, et al. [Article:17015050@PubMed] |
|
|
Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance. Clinical pharmacology and therapeutics. 2006. Hukkanen Janne, et al. [Article:17112808@PubMed] |
|
|
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. European journal of clinical pharmacology. 2006. Al Koudsi Nael, et al. [Article:16758265@PubMed] |
|
|
Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract. International journal of cancer. Journal international du cancer. 2006. He Xiao-Yang, et al. [Article:16385575@PubMed] |
|
|
Cytochrome P450s and other enzymes in drug metabolism and toxicity. The AAPS journal. 2006. Guengerich F Peter. [Article:16584116@PubMed] |
|
|
Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 2006. Minematsu N, et al. [Article:16452582@PubMed] |
|
|
Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. The Journal of pharmacology and experimental therapeutics. 2006. von Weymarn Linda B, et al. [Article:16188955@PubMed] |
|
|
CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. The pharmacogenomics journal. 2006. Kubota T, et al. [Article:16402086@PubMed] |
|
|
CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. The pharmacogenomics journal. 2006. Fukami T, et al. [Article:16636685@PubMed] |
|
|
Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicological sciences : an official journal of the Society of Toxicology. 2006. Kiang Tony K L, et al. [Article:16945988@PubMed] |
|
|
Identification of N-(hydroxymethyl) norcotinine as a major product of cytochrome P450 2A6, but not cytochrome P450 2A13-catalyzed cotinine metabolism. Chemical research in toxicology. 2005. Brown Kathryn M, et al. [Article:16359169@PubMed] |
|
|
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clinical pharmacology and therapeutics. 2005. Malaiyandi Viba, et al. [Article:15735609@PubMed] |
|
|
CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug metabolism and disposition: the biological fate of chemicals. 2005. Yamanaka Hiroyuki, et al. [Article:16135656@PubMed] |
|
|
Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug metabolism and disposition: the biological fate of chemicals. 2005. Fukami Tatsuki, et al. [Article:15900015@PubMed] |
|
|
Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. Drug metabolism and disposition: the biological fate of chemicals. 2005. Murphy Sharon E, et al. [Article:15860657@PubMed] |
|
|
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Investigational new drugs. 2005. van Schaik Ron H N. [Article:16267627@PubMed] |
|
|
Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nature structural & molecular biology. 2005. Yano Jason K, et al. [Article:16086027@PubMed] |
|
|
CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents. Pharmacogenetics and genomics. 2005. Huang Shuwen, et al. [Article:16272956@PubMed] |
|
|
Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenetics and genomics. 2005. Mwenifumbo Jill C, et al. [Article:15861044@PubMed] |
|
|
Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenetics and genomics. 2005. Swan Gary E, et al. [Article:15861035@PubMed] |
|
|
Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. The pharmacogenomics journal. 2005. Gambier N, et al. [Article:15940289@PubMed] |
|
|
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clinical pharmacology and therapeutics. 2004. Fukami Tatsuki, et al. [Article:15592323@PubMed] |
|
|
Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 2004. Schoedel Kerri A, et al. [Article:15475735@PubMed] |
|
|
Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese. Pharmacogenetics. 2004. Ariyoshi Noritaka, et al. [Article:15454735@PubMed] |
|
|
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tobacco control. 2004. O'Loughlin J, et al. [Article:15564629@PubMed] |
|
|
Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual review of pharmacology and toxicology. 2003. Ding Xinxin, et al. [Article:12171978@PubMed] |
|
|
Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer research. 2003. Wang Haijian, et al. [Article:14633739@PubMed] |
|
|
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clinical pharmacology and therapeutics. 2003. Yoshida Ryoko, et al. [Article:12844137@PubMed] |
|
|
The contribution of cytochrome P450 to the metabolism of tegafur in human liver. Drug metabolism and pharmacokinetics. 2003. Kajita Jiro, et al. [Article:15618749@PubMed] |
|
|
Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics. 2003. Kiyotani Kazuma, et al. [Article:14583682@PubMed] |
|
|
Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug metabolism and pharmacokinetics. 2002. Kiyotani Kazuma, et al. [Article:15618701@PubMed] |
|
|
Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Human mutation. 2002. Oscarson Mikael, et al. [Article:12325023@PubMed] |
|
|
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular pharmacology. 2002. Maglich Jodi M, et al. [Article:12181440@PubMed] |
|
|
A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 2002. Daigo Satoshi, et al. [Article:12042667@PubMed] |
|
|
Characterization of a genotype previously designated as CYP2A6 D-type: CYP2A6*4B, another entire gene deletion allele of the CYP2A6 gene in Japanese. Pharmacogenetics. 2002. Ariyoshi Noritaka, et al. [Article:12172220@PubMed] |
|
|
Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochemical and biophysical research communications. 2001. Pitarque M, et al. [Article:11394901@PubMed] |
|
|
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). British journal of clinical pharmacology. 2001. Wen X, et al. [Article:11736863@PubMed] |
|
|
Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Clinical pharmacology and therapeutics. 2001. Nakajima M, et al. [Article:11180041@PubMed] |
|
|
Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics. 2001. Loriot M A, et al. [Article:11207029@PubMed] |
|
|
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. The Journal of pharmacology and experimental therapeutics. 2001. Rae J M, et al. [Article:11714868@PubMed] |
|
|
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer research. 2000. Su T, et al. [Article:11016631@PubMed] |
|
|
Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000. Ikeda K, et al. [Article:11106261@PubMed] |
|
|
CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug metabolism and disposition: the biological fate of chemicals. 2000. Donato M T, et al. [Article:11038160@PubMed] |
|
|
Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2000. Komatsu T, et al. [Article:11095583@PubMed] |
|
|
Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Molecular pharmacology. 2000. Rao Y, et al. [Article:10999944@PubMed] |
|
|
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica; the fate of foreign compounds in biological systems. 2000. Meunier V, et al. [Article:10923861@PubMed] |
|
|
Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of toxicology. 1999. Yamazaki H, et al. [Article:10350185@PubMed] |
|
|
Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. British journal of clinical pharmacology. 1999. Svensson U S, et al. [Article:10583023@PubMed] |
|
|
Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS letters. 1999. Oscarson M, et al. [Article:10544257@PubMed] |
|
|
Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. The Journal of pharmacology and experimental therapeutics. 1997. Sadeque A J, et al. [Article:9353388@PubMed] |
|
|
Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug metabolism and disposition: the biological fate of chemicals. 1996. Nakajima M, et al. [Article:8937855@PubMed] |
|
|
Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. The Journal of pharmacology and experimental therapeutics. 1996. Nakajima M, et al. [Article:8627511@PubMed] |
|
|
O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Molecular pharmacology. 1994. Relling M V, et al. [Article:8114683@PubMed] |
|
|
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. The Journal of pharmacology and experimental therapeutics. 1994. Shimada T, et al. [Article:8035341@PubMed] |
|
|
The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 1990. Yamano S, et al. [Article:2322567@PubMed] |
|
|
Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. The Biochemical journal. 1990. Miles J S, et al. [Article:2334398@PubMed] |
